First RGH patient joins clinical trial for chemotherapy free cancer treatment
Kenny Muguti (third from left) with members of the Haematology Unit.
For Kenny Muguti, being diagnosed with chronic lymphocytic leukaemia (CLL) came as a shock, but after some careful consideration he is participating in a new clinical trial being led out of Rockingham General Hospital (RGH) exploring a chemotherapy-free approach to treating the condition.
CLL is one of the most common types of blood cancer, accounting for 30 percent of all new leukaemia cases in Australia.
Kenny, who has worked at the hospital for 17 years as a registered nurse, said his diagnosis came as a surprise, having prioritised his health and fitness.
“I have always tried to live a healthy lifestyle with regular exercise, and I wasn’t on any regular medication,” said Kenny.
Even after blood tests confirmed his diagnosis, Kenny notes he still doesn’t have symptoms – one of the challenges associated with CLL, which often presents with little or no symptoms, which is why routine check-ups are essential.
The clinical trial consists solely of oral tablets, providing greater convenience and improved quality of life for patients with newly diagnosed CLL.
Both medications have already been proven safe and effective when used separately, and researchers are now exploring whether using them together offers even better results, while maintaining fewer side effects than chemotherapy.
Although hesitant at first, Kenny consulted his doctors and friends and decided to just ‘go for it’.
“At first, I was a bit scared and overwhelmed with all the information I was receiving, but after doing some reading and talking to people I decided to go for it – what do I have to lose?” said Kenny.
“I liken being involved in the trial to having an iPhone 5 and upgrading to an iPhone 6 –you’re always going to opt for the latest version.”
Kenny is keen to contribute to the future of blood cancer treatment.
“I’ve always prided myself on being positive and it’s something I’m trying to continue now, and I know that even if it doesn’t work for me, it should hopefully help others,” said Kenny.
Kenny is the first RGH patient to participate in a clinical trial through the RGH Haematology Clinical Trials Unit which is committed to providing patient-centred care by participating in cutting-edge research.
Consultant Haematologist A/Prof Collin Chin said welcoming Kenny as the first patient to participate in clinical trials at RGH was a major step in advancing treatment and outcomes for people in the region.
“Clinical trials are essential for advancing cancer treatment and ensuring patients have access to the latest medical innovations,” said Collin.
“This trial represents a significant step forward in improving care for patients with CLL –offering hope for a future where effective, low-toxicity treatments are becoming the new standard of care.”
Patients and clinicians interested in learning more about the available trials at RGH are encouraged to email the Haematology Clinical Trials Unit for further details.
Keep up to date with our news and achievements
Find out more on Facebook (external site) or LinkedIn (external site)